Dashboard PDUFA PDUFA History Dilution Watch Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Track TCRT with free AI briefings, catalyst countdowns, and dilution alerts.

TCRT · Alaunos Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$124,000 Cash on Hand

0.6mo Cash Runway

Follow TCRT by email Get an email when TCRT pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about TCRT, unsubscribe in one click. Privacy

🧪 Trial & FDA Catalysts

May 2025 · N/A · Results Expected · Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping B
Registry primary completion date, not a results date
Oct 2020 · Phase 1 · Results Expected · A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Gli
Registry primary completion date, not a results date
Aug 2019 · Phase 1 · Results Expected · A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma
Registry primary completion date, not a results date
Apr 2019 · Phase 1 · Results Expected · Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblas
Registry primary completion date, not a results date
Sep 2014 · Phase 1/2 · Results Expected · Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activat
Registry primary completion date, not a results date
May 2013 · Phase 1/2 · Results Expected · Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer
Registry primary completion date, not a results date

📊 Drug Pipeline

Drug	Indication	Most advanced trial	Status
Palifosfamide Tromethamine	Extensive-Stage Small Cell Lung Cancer	Phase 3 · NCT01555710	Terminated
Palifosfamide (ZIO-201)	Advanced Sarcoma	Phase 1/2 · NCT00439686	Completed
Darinaparsin (ZIO-101)	Multiple Myeloma	Phase 1/2 · NCT00303199	Completed
Veledimex (INXN-1001)	Metastatic Breast Cancer	Phase 1/2 · NCT02423902	Terminated
Oral Veledimex - Arm 2 (DIPG)	Pediatric Brain Tumor	Phase 1/2 · NCT03330197	Terminated
Oral Veledimex - Arm 1 (Pediatric Brain	Pediatric Brain Tumor	Phase 1/2 · NCT03330197	Terminated
Neoantigen specific TCR-T cell drug prod	Gynecologic Cancer	Phase 1/2 · NCT05194735	Terminated
Ad-RTS-hIL-12	Melanoma	Phase 1/2 · NCT01397708	Completed
Indibulin	Metastatic Breast Cancer	Phase 1/2 · NCT01113970	Completed
Doxorubicin	Soft Tissue Sarcoma	Phase 2 · NCT00718484	Terminated
DNA Damage-Inducible Transcript 3 Protei	Lymphoma	Phase 1 · NCT01139359	Withdrawn
Melphalan	Lymphoma	Phase 1 · NCT00968760	Completed
INXN-3001	Melanoma	Phase 1 · NCT00815607	Completed

Also used in these trials (approved or third-party drugs, not TCRT's own candidates): Carboplatin, Etoposide, Aldesleukin, Cemiplimab-Rwlc, Capecitabine, Carmustine, Cytarabine, Nivolumab, Erlotinib Hydrochloride, Interleukin-2.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

TCRT holds $124,000 in cash and short-term investments (as of Jun 30, 2026) and burns about $665,500/quarter from operations, an estimated runway of 0.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 47 · Elevated

Cash runway 1 months +40
Share count +16% in a year +7

Recent financing filings on SEC EDGAR:

Jun 26, 2025 · Private placement (8-K Item 3.02) · 8-K
Jun 10, 2025 · Private placement (8-K Item 3.02) · 8-K
May 23, 2025 · Private placement (8-K Item 3.02) · 8-K
Apr 14, 2025 · Private placement (8-K Item 3.02) · 8-K

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when TCRT files for a raise →

Get the full TCRT picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TCRT and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z